SIRT1 contributes to neuroendocrine differentiation of prostate cancer

被引:25
|
作者
Ruan, Lin [1 ,2 ]
Wang, Lei [3 ]
Wang, Xiaosong [1 ,4 ]
He, Ming [1 ,4 ]
Yao, Xiaoguang [1 ,4 ]
机构
[1] Hebei Univ Chinese Med, Hebei Key Lab Integrat Med Liver Kidney Patterns, Shijiazhuang, Hebei, Peoples R China
[2] Hebei Med Univ, Dept Nephrol, Hosp 1, Shijiazhuang, Hebei, Peoples R China
[3] Hebei Med Univ, Dept Urol, Hosp 1, Shijiazhuang, Hebei, Peoples R China
[4] Hebei Univ Chinese Med, Coll Integrat Med, Shijiazhuang, Hebei, Peoples R China
关键词
prostate cancer; SIRT1; neuroendocrine; N-Myc; Akt; OXIDATIVE STRESS; CELL-SURVIVAL; RESISTANT; EXPRESSION; P53; PROMOTES; MODULATION; APOPTOSIS; AUTOPHAGY; GENOMICS;
D O I
10.18632/oncotarget.23111
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The epigenetic factor SIRT1 can promote prostate cancer progression, but it is unclear whether SIRT1 contributes to neuroendocrine differentiation. In this study, we showed that androgen deprivation can induce reactive oxygen species production and that reactive oxygen species, in turn, activate SIRT1 expression. The increased SIRT1 expression induces neuroendocrine differentiation of prostate cancer cells by activating the Akt pathway. In addition, the interaction between Akt and SIRT1 is independent of N-Myc and can drive the development of neuroendocrine prostate cancer when N-Myc is blocked. Furthermore, SIRT1 facilitates tumor maintenance, and targeting SIRT1 may reduce the tumor burden during androgen deprivation. Our findings suggest that SIRT1 is a potential target for therapeutic intervention.
引用
收藏
页码:2002 / 2016
页数:15
相关论文
共 50 条
  • [1] Molecular mechanisms of neuroendocrine differentiation in prostate cancer progression
    Xie, Yuchen
    Ning, Songyi
    Hu, Jianpeng
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2022, 148 (07) : 1813 - 1823
  • [2] Neuroendocrine differentiation in prostate cancer
    Sun, Yin
    Niu, Junyang
    Huang, Jiaoti
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2009, 1 (02): : 148 - 162
  • [3] The expression and correlation of SIRT1 and Phospho-SIRT1 in colorectal cancer
    Zhang, Xianzhen
    Chen, Suiqin
    Cheng, Meili
    Cao, Fangli
    Cheng, Yufeng
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 8 (01): : 809 - 817
  • [4] Molecular aspects of prostate cancer with neuroendocrine differentiation
    Li, Qi
    Zhang, Connie S.
    Zhang, Yifen
    CHINESE JOURNAL OF CANCER RESEARCH, 2016, 28 (01) : 122 - 129
  • [5] SIRT1: a novel regulator in colorectal cancer
    Dong, Weiwei
    Lu, Jinjing
    Li, You
    Zeng, Juan
    Du, Xiaoyun
    Yu, Ao
    Zhao, Xuechan
    Chi, Feng
    Xi, Zhuo
    Cao, Shuo
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 178
  • [6] Active regulator of SIRT1 is required for cancer cell survival but not for SIRT1 activity
    Knight, John R. P.
    Allison, Simon J.
    Milner, Jo
    OPEN BIOLOGY, 2013, 3 (11)
  • [7] Enhanced autophagy promotes radiosensitivity by mediating Sirt1 downregulation in RM-1 prostate cancer cells
    Wang, Kai-Xuan
    Yan, Chen
    Yang, Xu
    Zhu, Pei-Yan
    Cui, Wen-Wen
    Ye, Cong
    Hu, Kan
    Lan, Ting
    Huang, Lin-Yan
    Wang, Wan
    Ma, Ping
    Qi, Su-Hua
    Gu, Bing
    Luo, Lan
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2022, 609 : 84 - 92
  • [8] SIRT1: new avenues of discovery for disorders of oxidative stress
    Chong, Zhao Zhong
    Shang, Yan Chen
    Wang, Shaohui
    Maiese, Kenneth
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2012, 16 (02) : 167 - 178
  • [9] Inhibition of glycolysis and SIRT1/GLUT1 signaling ameliorates the apoptotic effect of Leptosidin in prostate cancer cells
    Park, Youngsang
    Lee, Hyo-Jung
    Sim, Deok Yong
    Park, Ji Eon
    Ahn, Chi-Hoon
    Park, Su-Yeon
    Lee, Yu-Chan
    Shim, Bum-Sang
    Kim, Bonglee
    Kim, Sung-Hoon
    PHYTOTHERAPY RESEARCH, 2024, 38 (03) : 1235 - 1244
  • [10] Sirt1 is a tumor promoter in lung adenocarcinoma
    Chen, Xue
    Hokka, Daisuke
    Maniwa, Yoshimasa
    Ohbayashi, Chiho
    Itoh, Tomoo
    Hayashi, Yoshitake
    ONCOLOGY LETTERS, 2014, 8 (01) : 387 - 393